期刊文献+

吸烟与CYP2C19功能缺失性等位基因的交互作用对急性冠脉综合征患者氯吡格雷抗血小板反应性的影响

THE INTERACTION OF SMOKING STATUS AND CYP2C19 LOSS-OF-FUNCTION ALLELES ON PLATELET REACTIVITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH CLOPIDOGREL
原文传递
导出
摘要 目的探讨吸烟和CYP2C19功能缺失性等位基因交互作用对氯吡格雷抗血小板反应性的影响。方法该研究连续募集2011年9月—2013年9月解放军总医院住院并接受阿司匹林和氯吡格雷双联抗血小板治疗的急性冠脉综合征(ACS)患者。采用光密度比浊法(LTA)测定氯吡格雷治疗前后的血小板聚集率,SnaPshot法检测CYP2C19功能缺失性等位基因变异型。利用单因素和多因素统计方法,分析吸烟和CYP2C19基因型交互作用对氯吡格雷治疗前后的血小板聚集率和治疗期间高血小板反应性(HPR)的影响。结果该研究共纳入500例患者,吸烟组203例(40.6%),非吸烟组297例(59.4%)。在非吸烟组,氯吡格雷治疗后的稳定血小板聚集率在CYP2C19*2携带者(*1/*2:43.24±19.39;*2/*2:53.52±19.88)和非携带者(*1/*1:37.91±19.12)之间差异均有统计学意义(校对后P值分别为P=0.029,P<0.001);而在吸烟组中未见上述差异。非吸烟组中至少一个CYP2C19*2等位基因携带者与非携带者之间的HPR的发生率差异有统计学意义(校正后OR:2.13,95%CI:1.23-3.72,P=0.008),而在吸烟组中未见上述差异(校正后OR:1.41;95%CI:0.65-3.04,P=0.387)。结论吸烟和CYP2C19功能缺失性等位基因的交互作用能够影响ACS患者中氯吡格雷的抗血小板反应性。 Objective To investigate the interaction of smoking status and CYP2C19 lose-of-function alleles on platelet reactivity in acute coronary syndrome(ACS)patients treated with clopidogrel.MethodsConsecutive ACS patients on aspirin and clopidogrel dual antiplatelet therapy were enrolled from September1 st,2011 to September 1st,2013 from Chinese PLA General Hospital.ADP-induced platelet aggregation was measured by light transmission aggregation(LTA)before clopidogrel administration and after 5 days maintenance dose of clopidogrel.SnaPshot method was applied to detect CYP2C19 loss-of-function alleles.The interaction between smoking status and CYP2C19 alleles of platelet aggregation before and after clopidogrel therapy,as well as high on-treatment platelet reactivity(HTPR)were analyzed by univariate analysis and multivariate analysis.Results A total of 500 ACS patients on maintenance aspirin and clopidogrel therapy were enrolled,including 203 smokers(40.6%)and 297 nonsmokers(59.4%).In nonsmokers,a significant difference between CYP2C19*2 carriers(*1/*2:43.24±19.39;*2/*2:53.52±19.88)and non-carriers(*1/*1:37.91±19.12)of clopidogrel platelet aggregation(adjusted P=0.029,P〈0.001,respectively)could be observed,but no significance in smokers.In addition,clopidogrel on-treatment platelet reactivity was significantly different between CYP2C19*2 carriers and non-carriers(adjusted OR:2.13,95%CI:1.23-3.72,P=0.008)in non-smokers however,we didn't find the significance between CYP2C19*2 carriers and non-carriers(adjusted OR:1.41;95%CI:0.65-3.04,P=0.387)in smokers.Conclusion This study indicates that the interaction of smoking status and CYP2C19 lose-of-function alleles can effect platelet reactivity in ACS patients treated with clopidogrel.
出处 《中国煤炭工业医学杂志》 2014年第11期1721-1725,共5页 Chinese Journal of Coal Industry Medicine
基金 国家自然科学基金面上项目(30971259 30570736 81100215/C03030201) 解放军总医院临床扶持基金(No.2012FC-TSYS-3043)
关键词 吸烟 氯吡格雷 急性冠脉综合征 CYP2C19功能缺失性等位基因 抗血小板反应性 Smoking Clopidogrel Acute coronary syndrome CYP2C19 lose-of-function alleles Platelet reactivity
  • 相关文献

参考文献1

二级参考文献32

  • 1Gurbel PA,Bliden KP,Hayes KM,Yoho JA,Herzog WR,Tantry US.The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.J Am Coll Cardiol 2005; 45:1392-1396. 被引量:1
  • 2Desai NR,Mega JL,Jiang S,Cannon CP,Sabatine MS.Interaction between cigarette smoking and clinical benefit of clopidogrel.J Am Coll Cardio12009; 53:1273-1278. 被引量:1
  • 3de Morais SM,Wilkinson GR,Blaisdell J,Nakamura K,Meyer UA,Goldstein JA.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.J Biol Chem 1994; 269:15419-15422. 被引量:1
  • 4Goldstein JA.Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br J Clin Pharmacol 2001; 52:349-355. 被引量:1
  • 5Bertilsson L.Geographical/interracial differences in polymorphic drug oxidation.Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet 1995; 29:192-209. 被引量:1
  • 6Motovska Z,Widimsky P,Petr R,Bilkova D,Marinov I,Simek S,et al.Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention:statin's advantage and the smoking "paradox".J Cardiovasc Pharmacol 2009; 53:368-372. 被引量:1
  • 7Price MJ,Nayak KR,Barker CM,Kandzari DE,Teirstein PS.Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.Am J Cardiol 2009; 103:1339-1343. 被引量:1
  • 8Yang G,Fan L,Tan J,Qi G,Zhang Y,Samet JM,et al.Smoking in China:findings of the 1996 National Prevalence Survey.JAMA 1999; 282:1247-1253. 被引量:1
  • 9Gu D,Wu X,Reynolds K,Duan X,Xin X,Reynolds RF,et al.Cigarette smoking and exposure to environmental tobacco smoke in China:the international collaborative study of cardiovascular disease in Asia.Am J Public Health 2004; 94:1972-1976. 被引量:1
  • 10Varenhorst C,James S,Erlinge D,Brandt JT,Braun OO,Man M,et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.Eur Heart J 2009; 30:1744-1752. 被引量:1

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部